The firm has been a long-term legal advisor to this company on regulatory issues and has represented it at the Ministry of Health, the State Medicines Control Agency, and other state institutions. TGS Baltic has also contributed to the development and installation of Sicor Biotech's Good Manufacturing Practice (GMP) medicinal product system.
In 2004, Sicor Biotech was bought by Teva Pharmaceutical Industries Ltd., a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva, headquartered in Israel, is among the top 15 pharmaceutical companies and is one of the largest generic pharmaceutical companies in the world. More than 80% of Teva's sales are in North America and Europe. With more than 35,000 employees worldwide, Teva has production facilities in Israel, North America, Europe and Latin America.
In 2006, the Baltic Teva and IVAX representative offices were incorporated into Sicor Biotech, one Lithuania's largest biotech companies. This made it possible to expand the supply of drug products by Teva into the Baltics and other Eastern- and Central-European countries. The company's representatives distribute the drug products produced at Teva's European, Northern American, and Middle Eastern plants to Polish, Czech, Slovakian as well as Russian, Byelorussian, Kazakh, and other CIS markets.